<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BETOPTIC- betaxolol hydrochloride solution/ drops </strong><br>Alcon<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1> DESCRIPTION</h1>
<p class="First">BETOPTIC® Sterile Ophthalmic Solution contains betaxolol hydrochloride, a cardioselective beta-adrenergic receptor blocking agent, in a sterile isotonic solution.  Betaxolol hydrochloride is a white, crystalline powder, soluble in water, with a molecular weight of 343.89.  The chemical structure is presented below:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=31b9b263-11fd-4495-83dd-ababf0d70e9e&amp;name=Betoptic-01.jpg"></div>
<p>Empirical Formula:<br>     
C<span class="Sub">18</span>H<span class="Sub">29</span>NO<span class="Sub">3</span>•HCl<br>
Chemical Name:<br>     (±)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride.</p>
<p>Each mL of BETOPTIC Ophthalmic Solution (0.5%) contains:  <span class="Bold">Active</span>:  5.6 mg betaxolol hydrochloride equivalent to betaxolol base 5 mg.  <span class="Bold">Preservative</span>:  Benzalkonium Chloride 0.01%.  <span class="Bold">Inactive</span>:  Edetate Disodium, Sodium Chloride, Hydrochloric Acid and/or Sodium Hydroxide (to adjust pH), and Purified Water.    DM-00</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1> CLINICAL PHARMACOLOGY</h1>
<p class="First">Betaxolol HCl, a cardioselective (beta-1-adrenergic) receptor blocking agent, does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action.  Orally administered beta-adrenergic blocking agents reduce <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> in healthy subjects and patients with heart disease.  In patients with severe impairment of myocardial function, beta-adrenergic receptor antagonists may inhibit the sympathetic stimulatory effect necessary to maintain adequate cardiac function.</p>
<p>When instilled in the eye, BETOPTIC Ophthalmic Solution has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.  Ophthalmic betaxolol has minimal effect on pulmonary and cardiovascular parameters.</p>
<p>Ophthalmic betaxolol (one drop in each eye) was compared to timolol and placebo in a three-way crossover study challenging nine patients with reactive airway disease who were selected on the basis of having at least a 15% reduction in the forced expiratory volume in one second (FEV<span class="Sub">1</span>) after administration of ophthalmic timolol.  Betaxolol HCl had no significant effect on pulmonary function as measured by FEV<span class="Sub">1</span>.  Forced <span class="product-label-link" type="condition" conceptid="4147814" conceptname="Vital capacity">Vital Capacity</span> (FVC) and FEV<span class="Sub">1</span>/VC.  Additionally, the action of isoproteranol, a beta stimulant, administered at the end of the study was not inhibited by ophthalmic betaxolol.  In contrast, ophthalmic timolol significantly decreased these pulmonary functions.</p>
<a name="Le6359adf-03a4-461e-b119-eefda18179ce"></a><table width="100%">
<caption><span>FEV<span class="Sub">1</span> - Percent Change From Baseline<span class="Sup">1 </span></span></caption>
<colgroup>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
</colgroup>
<thead>
<tr class="First">
<td></td>
<td align="center" colspan="3">Means</td>
</tr>
<tr class="Last">
<td></td>
<td align="center">Betaxolol 1.0%<span class="Sup">a</span>
</td>
<td align="center">Timolol 0.5%</td>
<td align="center">Placebo</td>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="100">
<p class="First"><span class="Sup">1</span>Schoene, R. B. <span class="Italics">et al.,</span> Am. J. Ophthal. 97:86, 1984.</p>
<p><span class="Sup">a</span>Twice the clinical concentration.</p>
<p><span class="Sup">b</span>Inhaled at 240 minutes; measurement at 270 minutes.</p>
<p>*Timolol statistically different from betaxolol and placebo (p &lt; 0.05).</p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td align="center">Baseline</td>
<td align="center">1.6</td>
<td align="center">1.4</td>
<td align="center">1.4</td>
</tr>
<tr>
<td align="center">60 minutes</td>
<td align="center">2.3</td>
<td align="center">-25.7*</td>
<td align="center">5.8</td>
</tr>
<tr>
<td align="center">120 Minutes</td>
<td align="center">1.6</td>
<td align="center">-27.4*</td>
<td align="center">7.5</td>
</tr>
<tr>
<td align="center">240 Minutes</td>
<td align="center">-6.4</td>
<td align="center">-26.9*</td>
<td align="center">6.9</td>
</tr>
<tr class="Last">
<td align="center">Isoproternol<span class="Sup">b</span>
</td>
<td align="center">36.1</td>
<td align="center">-12.4*</td>
<td align="center">42.8</td>
</tr>
</tbody>
</table>
<p>No evidence of cardiovascular beta-adrenergic blockade during exercise was observed with betaxolol in a double-masked, three-way crossover study in 24 normal subjects comparing ophthalmic betaxolol, timolol and placebo for effect on blood pressure and heart rate.  Mean arterial blood pressure was not affected by any treatment; however, ophthalmic timolol produced a significant decrease in the mean heart rate.</p>
<a name="L59f7ea66-6082-4c1d-a28a-42abf5ef673d"></a><table width="100%">
<caption><span>Mean Heart Rates<span class="Sup">1 </span></span></caption>
<colgroup>
<col width="35%">
<col width="24%">
<col width="23%">
<col width="17%">
</colgroup>
<thead>
<tr class="First">
<td align="center"></td>
<td align="center" colspan="3">TREATMENT</td>
</tr>
<tr>
<td align="center">Bruce Stress Exercise Test</td>
<td align="center" colspan="3"></td>
</tr>
<tr class="Last">
<td align="center">Minutes</td>
<td align="center">Betaxolol 1%<span class="Sup">a</span>
</td>
<td align="center">Timolol 0.5%</td>
<td align="center">Placebo</td>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="100">
<p class="First"><span class="Sup">1</span>Atkins, J. M. <span class="Italics">et. al</span>., Am. J. Oph. 99:173-175, Feb., 1985.</p>
<p><span class="Sup">a</span>Twice the clinical concentration.</p>
<p>*Mean pulse rate significantly lower for timolol than betaxolol or placebo (p &lt; 0.05).</p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td align="center">0</td>
<td align="center">79.2</td>
<td align="center">79.3</td>
<td align="center">81.2</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">130.2</td>
<td align="center">126.0</td>
<td align="center">130.4</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">133.4</td>
<td align="center">128.0*</td>
<td align="center">134.3</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">136.4</td>
<td align="center">129.2*</td>
<td align="center">137.9</td>
</tr>
<tr>
<td align="center">8</td>
<td align="center">139.8</td>
<td align="center">131.8*</td>
<td align="center">139.4</td>
</tr>
<tr class="Last">
<td align="center">10</td>
<td align="center">140.8</td>
<td align="center">131.8*</td>
<td align="center">141.3</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="34092-7">
<a name="section-3.1"></a><p></p>
<h2> Clinical Studies</h2>
<p class="First">Optic nerve head damage and visual field loss are the result of a sustained elevated intraocular pressure and poor ocular perfusion.  BETOPTIC Ophthalmic Solution has the action of reducing elevated as well as normal intraocular pressure, and the mechanism of ocular hypotensive action appears to be a reduction of aqueous production as demonstrated by tonography and aqueous fluorophotometry.  The onset of action with BETOPTIC Ophthalmic Solution can generally be noted within 30 minutes and the maximal effect can usually be detected 2 hours after topical administration.  A single dose provides a 12-hour reduction in intraocular pressure.  Clinical observation of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> patients treated with BETOPTIC Ophthalmic Solution for up to three years shows that the intraocular pressure lowering effect is well maintained.</p>
<p>Clinical studies show that topical BETOPTIC Ophthalmic Solution reduces mean intraocular pressure 25% from baseline.  In trials using 22 mmHg as a generally accepted index of intraocular pressure control, BETOPTIC Ophthalmic Solution was effective in more than 94% of the population studied, of which 73% were treated with the beta blocker alone.  In controlled, double-masked studies, the magnitude and duration of the ocular hypotensive affect of BETOPTIC Ophthalmic Solution and ophthalmic timolol solution were clinically equivalent.</p>
<p>BETOPTIC Ophthalmic Solution has also been used successfully in <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> patients who have undergone a laser trabeculoplasty and have needed additional long-term ocular hypotensive therapy.</p>
<p>BETOPTIC Ophthalmic Solution has been well tolerated in <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> patients wearing hard or soft contact lenses and in aphakic patients.</p>
<p>BETOPTIC Ophthalmic Solution does  not produce <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> or accommodative spasm which are frequently seen with miotic agents.  The <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> and <span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">night blindness</span> often associated with standard miotic therapy are not associated with BETOPTIC Ophthalmic Solution.  Thus, patients with central <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">lenticular opacities</span> avoid the <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span> caused by a constricted pupil.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1> INDICATIONS AND USAGE</h1>
<p class="First">BETOPTIC Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> and chronic open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.  It may be used alone or in combination with other anti-<span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> drugs.</p>
<p>In clinical studies BETOPTIC was safely used to lower intraocular pressure in 47 patients with both <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> and reactive airway disease who were followed for a mean period of 15 months.  However, caution should be used in treating patients with severe reactive airway disease or a history of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1> CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this product.  BETOPTIC Ophthalmic Solution is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, greater than a <span class="product-label-link" type="condition" conceptid="314379" conceptname="First degree atrioventricular block">first degree atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, or patients with overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1> WARNING</h1>
<p class="First">Topically applied beta-adrenergic blocking agents may be absorbed systemically.  The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration.  For example, severe respiratory reactions and cardiac reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and rarely <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in association with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, have been reported with topical application of beta-adrenergic blocking agents.</p>
<p>BETOPTIC® Ophthalmic Solution has been shown to have a minor effect on heart rate and blood pressure in clinical studies.  Caution should be used in treating patients with a history of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> or <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>.  Treatment with BETOPTIC Ophthalmic Solution should be discontinued at the first signs of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1> PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2> General</h2>
<p class="First">Information for Patients.  Do not touch dropper tip to any surface as this may contaminate the solution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2> <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</h2>
<p class="First">Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or to diabetic patients (especially those with labile <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are receiving insulin or oral hypoglycemic agents.  Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2> <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></h2>
<p class="First">Beta-adrenergic blocking agents may mask certain clinical signs (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>.  Patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents, which might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2> <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span></h2>
<p class="First">Beta-adrenergic blockade has been reported to potentiate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> consistent with certain myasthenic symptoms (e.g., diplopla, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, and generalized <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2> Major Surgery</h2>
<p class="First">Consideration should be given to the gradual withdrawal of beta-adrenergic blocking agents prior to general anesthesia because of the reduced ability of the heart to respond to beta-adrenergically mediated sympathetic reflex stimuli.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6"></a><p></p>
<h2> Pulmonary</h2>
<p class="First">Caution should be exercised in the treatment of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> patients with excessive restriction of pulmonary function.  There have been reports of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic attacks</span> and pulmonary distress during betaxolol treatment.  Although rechallenges of some such patients with ophthalmic betaxolol has not adversely affected pulmonary function test results, the possibility of adverse pulmonary effects in patients sensitive to beta blockers cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7"></a><p></p>
<h2> Risk from <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reaction</span></h2>
<p class="First">While taking beta-blockers, patients with a history of <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopy</span> or a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens.  Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.8"></a><p></p>
<h2> Drug Interactions</h2>
<p class="First">Patients who are receiving a beta-adrenergic blocking agent orally and BETOPTIC Ophthalmic Solution should be observed for a potential additive effect either on the intraocular pressure or on the known systemic effects of beta blockade.</p>
<p>Close observation of the patients is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</p>
<p>Betaxolol is an adrenergic blocking agent; therefore, caution should be exercised in patients using concomitant adrenergic psychotropic drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.9"></a><p></p>
<h2> Ocular</h2>
<p class="First">In patients with angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, the immediate treatment objective is to reopen the angle by constriction of the pupil with a miotic agent.  Betaxolol has little or no effect on the pupil.  When the BETOPTIC Ophthalmic Solution is used to reduce elevated intraocular pressure in angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, it should be used with a miotic and not alone.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.10"></a><p></p>
<h2> Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Lifetime studies with betaxolol HCl have been completed in mice at oral doses of 6, 20 or 60 mg/kg/day and in rats at 3, 12, or 48 mg/kg/day; betaxolol HCl demonstrated no carcinogenic effect.  Higher dose levels were not tested.</p>
<p>In a variety of <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> bacterial and mammalian cell assays, betaxolol HCl was nonmutagenic.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.11"></a><p></p>
<h2> Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category C.</span>  Reproduction, teratology, and peri- and postnatal studies have been conducted with orally administered betaxolol HCl in rats and rabbits.  There was evidence of drug related postimplantation loss in rabbits and rats at dose levels above 12 mg/kg and 128 mg/kg, respectively.  Betaxolol HCl was not shown to be teratogenic, however, and there were no other adverse effects on reproduction at subtoxic dose levels.  There are no adequate and well-controlled studies in pregnant women.  BETOPTIC Ophthalmic Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.12"></a><p></p>
<h2> Nursing Mothers</h2>
<p class="First">It is not known whether betaxolol HCl is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when BEOPTIC Ophthalmic Solution is administered to nursing women.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.13"></a><p></p>
<h2> Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1> ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions have been reported in clinical trials with BETOPTIC Ophthalmic Solution.  </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2> Ocular</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">Discomfort</span> of short duration was experienced by one  in four patients, but none discontinued therapy; occasional tearing has been reported.  Rare instances of decreased corneal sensitivity, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> sensation, corneal punctate staining, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="434374" conceptname="Anisocoria">anisocoria</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> have been reported.</p>
<p>Additional medical events reported with other formulations of betaxolol include <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, foreign body sensation, dryness of the eyes, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, discharge, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span>, decreased visual acuity, and crusty lashes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2> Systemic</h2>
<p class="First">Systemic reactions following administration of BETOPTIC Ophthalmic Solution 0.5% or BETOPTIC S Ophthalmic Suspension 0.25% have been rarely reported.  These include:</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2> Cardiovascular</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> and congestive failure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2> Pulmonary</h2>
<p class="First">Pulmonary distress characterized by <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, thickened bronchial secretions, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2> Central Nervous System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, and increase in signs and symptoms of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2> Other</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Hives</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span> and <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1> OVERDOSAGE</h1>
<p class="First">No information is available on overdosage of humans.  The oral LD<span class="Sub">50</span> of the drug ranged from 350-920 mg/kg in mice and 860-1050 mg/kg in rats.  The symptoms which might be expected with an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of a systemically administered beta-1-adrenergic receptor blocker agent are <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and acute <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>.  A topical <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of BETOPTIC Ophthalmic Solution may be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> from the eye(s) with warm tap water.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1> DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose is one to two drops of BETOPTIC Ophthalmic Solution in the affected eye(s) twice daily.  In some patients, the intraocular pressure lowering responses to BETOPTIC Ophthalmic Solution may require a few weeks to stabilize.  As with any new medication, careful monitoring of patients is advised.</p>
<p>If the intraocular pressure of the patient is not adequately controlled on this regimen, concomitant therapy with pilocarpine and other miotics, and/or epinephrine and/or carbonic anhydrase inhibitors can be instituted.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1> HOW SUPPLIED</h1>
<p class="First">BETOPTIC Ophthalmic Solution is a sterile, isotonic, aqueous solution of betaxolol hydrochloride.  Supplied as follows:  2.5, 5, 10 and 15 mL in plastic ophthalmic DROP-TAINER® dispensers.</p>
<p>2.5 mL:  NDC 0065-0245-20   10 mL: NDC 0065-0245-10</p>
<p>5 mL:  NDC 0065-0245-05   15 mL: NDC 0065-0245-15</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2> STORAGE</h2>
<p class="First">Store at room temperature</p>
<p><span class="Bold">Rx Only</span></p>
<p> U.S. Patents Nos. 4,252,984; 4,311,708; 4,342,783</p>
<p><span class="Bold">ALCON®</span></p>
<p><span class="Italics"><span class="Bold">OPHTHALMIC</span></span></p>
<p><span class="Bold">ALCON LABORATORIES, INC</span></p>
<p> Fort Worth,  Texas   76134   USA</p>
<p>Printed in  USA</p>
<p><span class="Bold">236015-0598</span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BETOPTIC 		
					</strong><br><span class="contentTableReg">betaxolol hydrochloride solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0065-0245</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>betaxolol hydrochloride</strong> (betaxolol) </td>
<td class="formItem"></td>
<td class="formItem">5.6 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem">0.1 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydrochloric acid and/or sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0065-0245-20</td>
<td class="formItem">2.5 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0065-0245-05</td>
<td class="formItem">5 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0065-0245-10</td>
<td class="formItem">10 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:0065-0245-15</td>
<td class="formItem">15 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Alcon</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0586E0A0-1962-3D4A-1A09-A543AF931CDF</div>
<div>Set id: 31b9b263-11fd-4495-83dd-ababf0d70e9e</div>
<div>Version: 1</div>
<div>Effective Time: 20061030</div>
</div>
</div> <div class="DistributorName">Alcon</div></p>
</body></html>
